Dr. McDonald on the Next Step for Angiogenesis Inhibitors

Video

Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Next Step for Angiogenesis Inhibitors

Donald M. McDonald, MD, PhD, a professor in the Department of Anatomy and an investigator in the Cardiovascular Research Institute at the University of California, San Francisco Comprehensive Cancer Center, explains that in the early stages of treatment with angiogenesis inhibitors the sky was believed to be the limit.

It was believed that blocking angiogenesis could stop tumor growth and keep tumors in a dormant state. Some cancers see great benefit, but limitations have become evident, particularly in breast cancer. Overcoming the limitations of inhibiting angiogenesis will be the next research step to take.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD